Segment - Schedule of Significant Expense Categories Within Net Loss Presented on the Statement of Operations (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Segment Reporting [Abstract] | ||||||
| Research and engineering expenses | $ 29,730 | $ 36,637 | $ 59,213 | $ 70,264 | ||
| Clinical expenses | 45,682 | 30,052 | 81,246 | 53,012 | ||
| In-process research and development expenses | 48 | 2,500 | 5,048 | 2,500 | ||
| Total research and development expenses | 75,460 | 69,189 | 145,507 | 125,776 | ||
| General and administrative expenses | 17,934 | 40,454 | 35,224 | 55,250 | ||
| Other segment items | (4,985) | (4,432) | (9,364) | (7,572) | ||
| Net loss | $ 88,409 | $ 82,958 | $ 105,211 | $ 68,243 | $ 171,367 | $ 173,454 |
| X | ||||||||||
- Definition Clinical expenses. No definition available.
|
| X | ||||||||||
- Definition In process research and development expenses. No definition available.
|
| X | ||||||||||
- Definition Research and engineering expenses. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|